Degron Therapeutics
Yong Cang is the Co-founder and CSO of Degron Therapeutics. He is a scientific leader in targeted protein degradation, ubiquitin ligase biology and cancer immunotherapy with 30+ publications in top biomedical journals. Dr. Cang pioneers novel molecular glue degrader discovery strategies, with a focus on screening approach development and mechanistic understanding of interactions between molecular glue drugs, ubiquitin ligases and neo-substrates. Dr. Cang is a professor and head of the Laboratory of Targeted Protein Degradation in the School of Life Science and Technology of ShanghaiTech University. He previously was an assistant professor in the NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute and a professor of Zhejiang University. Dr. Cang consulted for pharmaceutical industry and venture funds.
Dr. Cang received a BS from Fudan University and a PhD in Molecular Genetics from the Albert Einstein College of Medicine. He completed his postdoctoral training with Professor Stephen Goff at Columbia University and HHMI.
This person is not in any teams
This person is not in any offices
Degron Therapeutics
Dago Bio aims to become the world's leading research and development company for innovative protein degradation drugs-molecular glue-based small molecule new drugs. The Dago team, composed of world-class managers and scientific leaders with international vision and rich industry experience, will focus on the discovery and verification of new, especially undruggable targets of traditional small molecule inhibitors, and the optimization of new compounds. Provide innovative solutions and paths in preclinical and clinical research. It can be used in all therapeutic areas, with the mission of benefiting human health and addressing unmet clinical medical needs.